Zoster vaccine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Zoster vaccine" in English language version.

Last modified: 03:53:12, 13 July 2026 (UTC)

Ref.Un. Ref.Website

Global rank English rank

6540web.archive.org

1^st place

5126nih.gov

5^th place

2112doi.org

2^nd place

1810cdc.gov

251^st place

248^th place

74europa.eu

62^nd place

100^th place

55fda.gov

470^th place

329^th place

53nhs.uk

2,637^th place

2,254^th place

51aafp.org

2,559^th place

2,163^rd place

43ubc.ca

1,820^th place

998^th place

42merckvaccines.com

low place

22tga.gov.au

4,353^rd place

2,806^th place

21empr.com

low place

11drugs.com

529^th place

550^th place

11canada.ca

1,114^th place

605^th place

11medicines.org.uk

4,892^nd place

3,451^st place

11publishing.service.gov.uk

1,837^th place

948^th place

11walrus.com

low place

11pharmaceuticalonline.com

low place

11webmd.com

2,056^th place

1,884^th place

11rxlist.com

low place

11medicinenet.com

6,975^th place

7,170^th place

11fsu.edu

2,949^th place

1,945^th place

11semanticscholar.org

15^th place

8^th place

11gov.uk

401^st place

228^th place

11washingtonpost.com

35^th place

24^th place

11medpac.gov

low place

11stanford.edu

194^th place

182^nd place

aafp.org (Global: 2,559^th place; English: 2,163^rd place)

Saguil A, Kane S, Mercado M, Lauters R (November 2017). "Herpes zoster and postherpetic neuralgia: prevention and management". American Family Physician. 96 (10): 656–663. PMID 29431387. Archived from the original on 25 April 2021. Retrieved 19 February 2021.

canada.ca (Global: 1,114^th place; English: 605^th place)

"Vaccines". Health Canada. 9 May 2018. Retrieved 13 April 2024.

cdc.gov (Global: 251^st place; English: 248^th place)

cdc.gov

"What everyone should know about Zostavax". U.S. Centers for Disease Control and Prevention (CDC). 18 June 2018. Archived from the original on 17 November 2018. Retrieved 16 November 2018.
"Herpes Zoster Vaccination". U.S. Centers for Disease Control and Prevention (CDC). 31 July 2015. Archived from the original on 26 October 2021. Retrieved 26 October 2021.
"Shingles Vaccination". CDC. U.S. Centres for Disease Control and Prevention. 21 August 2025.
"Shingles Vaccination: What Everyone Should Know". U.S. Centers for Disease Control and Prevention (CDC). 24 May 2022. Archived from the original on 20 April 2018. Retrieved 1 January 2023.
"CDC's Advisory Committee Recommends "Shingles" Vaccination" (Press release). U.S. Centers for Disease Control and Prevention (CDC). 26 October 2006. Archived from the original on 5 November 2009. Retrieved 31 October 2009.
Harpaz R, Ortega-Sanchez IR, Seward JF (June 2008). "Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)" (PDF). MMWR. Recommendations and Reports. 57 (RR-5): 1–30, quiz CE2–4. PMID 18528318. Archived (PDF) from the original on 8 June 2021. Retrieved 6 September 2020.
Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, et al. (January 2018). "Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines" (PDF). MMWR. Morbidity and Mortality Weekly Report. 67 (3): 103–108. doi:10.15585/mmwr.mm6703a5. PMC 5812314. PMID 29370152. Archived (PDF) from the original on 29 August 2021. Retrieved 10 June 2023.
"Shingles (Herpes Zoster) Vaccination". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 7 December 2018.
"Frequently Asked Questions About Shingrix". U.S. Centers for Disease Control and Prevention (CDC). 26 March 2018. Archived from the original on 1 May 2021. Retrieved 23 January 2020. You and patients should make every effort to ensure that two doses are administered within the recommended 2–6 month interval. If more than 6 months have elapsed since the first dose, administer the second dose as soon as possible. Do not restart the vaccine series...

archive.cdc.gov

"What Everyone Should Know about Zostavax". CDC. Centre for Disease Control. 23 May 2023. Retrieved 1 June 2025.

doi.org (Global: 2^nd place; English: 2^nd place)

Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, et al. (July 2015). "Varicella zoster virus infection". Nature Reviews Disease Primers. 1 15016. doi:10.1038/nrdp.2015.16. PMC 5381807. PMID 27188665.
Tricco AC, Zarin W, Cardoso R, Veroniki AA, Khan PA, Nincic V, et al. (October 2018). "Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis". BMJ. 363 k4029. doi:10.1136/bmj.k4029. PMC 6201212. PMID 30361202.
Pan CX, Lee MS, Nambudiri VE (2022). "Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review". Therapeutic Advances in Vaccines and Immunotherapy. 10 25151355221084535. doi:10.1177/25151355221084535. PMC 8941701. PMID 35340552.
Gagliardi AM, Andriolo BN, Torloni MR, Soares BG, de Oliveira Gomes J, Andriolo RB, et al. (November 2019). "Vaccines for preventing herpes zoster in older adults". The Cochrane Database of Systematic Reviews. 2019 (11). doi:10.1002/14651858.CD008858.pub4. PMC 6836378. PMID 31696946.
de Oliveira Gomes J, Gagliardi AM, Andriolo BN, Torloni MR, Andriolo RB, Puga ME, et al. (Cochrane Acute Respiratory Infections Group) (October 2023). "Vaccines for preventing herpes zoster in older adults". The Cochrane Database of Systematic Reviews. 2023 (10) CD008858. doi:10.1002/14651858.CD008858.pub5. PMC 10542961. PMID 37781954.
Mitka M (July 2006). "FDA approves shingles vaccine: herpes zoster vaccine targets older adults". JAMA. 296 (2): 157–158. doi:10.1001/jama.296.2.157. PMID 16835412.
Pellissier JM, Brisson M, Levin MJ (November 2007). "Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults". Vaccine. 25 (49): 8326–8337. doi:10.1016/j.vaccine.2007.09.066. PMID 17980938.
Advisory Committee on Immunization Practices (November 2007). "Recommended adult immunization schedule: United States, October 2007-September 2008". Annals of Internal Medicine. 147 (10): 725–729. doi:10.7326/0003-4819-147-10-200711200-00187. PMID 17947396. S2CID 31630647.
Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, et al. (January 2018). "Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines" (PDF). MMWR. Morbidity and Mortality Weekly Report. 67 (3): 103–108. doi:10.15585/mmwr.mm6703a5. PMC 5812314. PMID 29370152. Archived (PDF) from the original on 29 August 2021. Retrieved 10 June 2023.
Le P, Rothberg MB (February 2018). "Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults". JAMA Internal Medicine. 178 (2): 248–258. doi:10.1001/jamainternmed.2017.7431. PMC 5838796. PMID 29297049.
- Taquet M, Dercon Q, Todd JA, Harrison PJ (October 2024). "The recombinant shingles vaccine is associated with lower risk of dementia". Nature Medicine. 30 (10): 2777–2781. doi:10.1038/s41591-024-03201-5. PMC 11485228. PMID 39053634.
- - Taquet M, Todd JA, Harrison PJ (June 2025). "Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections". npj Vaccines. 10 (1) 130. doi:10.1038/s41541-025-01172-3. PMC 12198376. PMID 40562756.
  drugs.com (Global: 529^th place; English: 550^th place)
  - "Zoster vaccine live (Zostavax) Use During Pregnancy". Drugs.com. 3 January 2020. Archived from the original on 16 May 2021. Retrieved 23 January 2020.
  empr.com (Global: low place; English: low place)
  - Han DH (25 October 2017). "ACIP: New Vaccine Recommendations for Shingles Prevention". MPR. Archived from the original on 11 May 2021. Retrieved 30 October 2017.
  europa.eu (Global: 62^nd place; English: 100^th place)
  ema.europa.eu
  - "Zostavax EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 5 August 2020. Retrieved 31 July 2020.
  - "Shingrix EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 4 August 2018. Retrieved 31 July 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  - "Zostavax EPAR" (PDF). European Medicines Agency (EMA). July 2006. Archived (PDF) from the original on 5 July 2019. Retrieved 27 March 2011.
  - "Zostavax-H-C-674-II-03 Scientific Discussion" (PDF). 21 June 2007. Archived (PDF) from the original on 5 July 2019. Retrieved 27 March 2011.
  fda.gov (Global: 470^th place; English: 329^th place)
  - "Patient Information about Zostavax". U.S. Food and Drug Administration (FDA). May 2006. Archived from the original on 19 June 2009. Retrieved 31 October 2009.
  - "Patient Information about Zostavax (Text) 12/2008". U.S. Food and Drug Administration (FDA). December 2008. Archived from the original on 27 August 2009. Retrieved 31 October 2009.
  - "FDA Shingrix Briefing Document" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on 2 November 2017. Retrieved 28 October 2017.
  - "FDA approves Zostavax vaccine to prevent shingles in individuals 50 to 59 years of age" (Press release). U.S. Food and Drug Administration (FDA). 24 March 2011. Archived from the original on 27 March 2011. Retrieved 27 March 2011.
  - "BBL approval" (PDF). U.S. Food and Drug Administration (FDA). 20 October 2017. Archived from the original (PDF) on 1 November 2017. Retrieved 29 April 2018.
  fsu.edu (Global: 2,949^th place; English: 1,945^th place)
  micro.magnet.fsu.edu
  - Davidson MW (13 November 2015). "Human Fetal Lung Fibroblast Cells (MRC-5 Line)". Florida State University. Archived from the original on 27 April 2021. Retrieved 6 September 2020.
  gov.uk (Global: 401^st place; English: 228^th place)
  - "Why you may have to wait for your shingles vaccine". GOV.UK. Retrieved 14 April 2024.
  medicinenet.com (Global: 6,975^th place; English: 7,170^th place)
  - "Shingles Vaccine (Zoster Shingles Vaccine Live, Zostavax)". Medicinenet.com. Archived from the original on 12 November 2017. Retrieved 29 April 2018.
  medicines.org.uk (Global: 4,892^nd place; English: 3,451^st place)
  - "Zostavax vaccine – Summary of Product Characteristics (SmPC)". (emc). 28 January 2019. Archived from the original on 16 May 2021. Retrieved 6 September 2020.
  medpac.gov (Global: low place; English: low place)
  - Report to the Congress: Medicare and the Health Care Delivery System. Medicare Payment Advisory Commission. June 2021. p. 254. Archived from the original on 24 May 2022. Retrieved 15 June 2022.
  merckvaccines.com (Global: low place; English: low place)
  - "About Zostavax". Merck Sharp & Dohme Corp. May 2018. Archived from the original on 17 November 2018. Retrieved 16 November 2018.
  - "Product Discontinuation Notice: Zostavax (Zoster Vaccine Live)" (PDF). Archived from the original (PDF) on 18 August 2020.
  nhs.uk (Global: 2,637^th place; English: 2,254^th place)
  - "Shingles Vaccination (16 July 2013, archived)". NHS UK. Archived from the original on 2 June 2014.
  - "Who can have the shingles vaccine? (16 July 2013, archived)". NHS UK. Archived from the original on 10 April 2014.
  - "Shingles vaccine overview". National Health Service (NHS). 31 August 2021. Archived from the original on 2 June 2014. Retrieved 26 November 2021.
  nih.gov (Global: 5^th place; English: 5^th place)
  pubmed.ncbi.nlm.nih.gov
  - Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, et al. (July 2015). "Varicella zoster virus infection". Nature Reviews Disease Primers. 1 15016. doi:10.1038/nrdp.2015.16. PMC 5381807. PMID 27188665.
  - Saguil A, Kane S, Mercado M, Lauters R (November 2017). "Herpes zoster and postherpetic neuralgia: prevention and management". American Family Physician. 96 (10): 656–663. PMID 29431387. Archived from the original on 25 April 2021. Retrieved 19 February 2021.
  - Tricco AC, Zarin W, Cardoso R, Veroniki AA, Khan PA, Nincic V, et al. (October 2018). "Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis". BMJ. 363 k4029. doi:10.1136/bmj.k4029. PMC 6201212. PMID 30361202.
  - Pan CX, Lee MS, Nambudiri VE (2022). "Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review". Therapeutic Advances in Vaccines and Immunotherapy. 10 25151355221084535. doi:10.1177/25151355221084535. PMC 8941701. PMID 35340552.
  - Gagliardi AM, Andriolo BN, Torloni MR, Soares BG, de Oliveira Gomes J, Andriolo RB, et al. (November 2019). "Vaccines for preventing herpes zoster in older adults". The Cochrane Database of Systematic Reviews. 2019 (11). doi:10.1002/14651858.CD008858.pub4. PMC 6836378. PMID 31696946.
  - Shah RA, Limmer AL, Nwannunu CE, Patel RR, Mui UN, Tyring SK (July 2019). "Shingrix for Herpes Zoster: A Review". Skin Therapy Letter. 24 (4): 5–7. PMID 31339679.
  - de Oliveira Gomes J, Gagliardi AM, Andriolo BN, Torloni MR, Andriolo RB, Puga ME, et al. (Cochrane Acute Respiratory Infections Group) (October 2023). "Vaccines for preventing herpes zoster in older adults". The Cochrane Database of Systematic Reviews. 2023 (10) CD008858. doi:10.1002/14651858.CD008858.pub5. PMC 10542961. PMID 37781954.
  - Mitka M (July 2006). "FDA approves shingles vaccine: herpes zoster vaccine targets older adults". JAMA. 296 (2): 157–158. doi:10.1001/jama.296.2.157. PMID 16835412.
  - Pellissier JM, Brisson M, Levin MJ (November 2007). "Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults". Vaccine. 25 (49): 8326–8337. doi:10.1016/j.vaccine.2007.09.066. PMID 17980938.
  - Harpaz R, Ortega-Sanchez IR, Seward JF (June 2008). "Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)" (PDF). MMWR. Recommendations and Reports. 57 (RR-5): 1–30, quiz CE2–4. PMID 18528318. Archived (PDF) from the original on 8 June 2021. Retrieved 6 September 2020.
  - Advisory Committee on Immunization Practices (November 2007). "Recommended adult immunization schedule: United States, October 2007-September 2008". Annals of Internal Medicine. 147 (10): 725–729. doi:10.7326/0003-4819-147-10-200711200-00187. PMID 17947396. S2CID 31630647.
  - Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, et al. (January 2018). "Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines" (PDF). MMWR. Morbidity and Mortality Weekly Report. 67 (3): 103–108. doi:10.15585/mmwr.mm6703a5. PMC 5812314. PMID 29370152. Archived (PDF) from the original on 29 August 2021. Retrieved 10 June 2023.
  - Le P, Rothberg MB (February 2018). "Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults". JAMA Internal Medicine. 178 (2): 248–258. doi:10.1001/jamainternmed.2017.7431. PMC 5838796. PMID 29297049.
  - Taquet M, Dercon Q, Todd JA, Harrison PJ (October 2024). "The recombinant shingles vaccine is associated with lower risk of dementia". Nature Medicine. 30 (10): 2777–2781. doi:10.1038/s41591-024-03201-5. PMC 11485228. PMID 39053634.
    Taquet M, Todd JA, Harrison PJ (June 2025). "Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections". npj Vaccines. 10 (1) 130. doi:10.1038/s41541-025-01172-3. PMC 12198376. PMID 40562756.
    ncbi.nlm.nih.gov
    Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, et al. (July 2015). "Varicella zoster virus infection". Nature Reviews Disease Primers. 1 15016. doi:10.1038/nrdp.2015.16. PMC 5381807. PMID 27188665.
    Tricco AC, Zarin W, Cardoso R, Veroniki AA, Khan PA, Nincic V, et al. (October 2018). "Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis". BMJ. 363 k4029. doi:10.1136/bmj.k4029. PMC 6201212. PMID 30361202.
    Pan CX, Lee MS, Nambudiri VE (2022). "Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review". Therapeutic Advances in Vaccines and Immunotherapy. 10 25151355221084535. doi:10.1177/25151355221084535. PMC 8941701. PMID 35340552.
    Gagliardi AM, Andriolo BN, Torloni MR, Soares BG, de Oliveira Gomes J, Andriolo RB, et al. (November 2019). "Vaccines for preventing herpes zoster in older adults". The Cochrane Database of Systematic Reviews. 2019 (11). doi:10.1002/14651858.CD008858.pub4. PMC 6836378. PMID 31696946.
    de Oliveira Gomes J, Gagliardi AM, Andriolo BN, Torloni MR, Andriolo RB, Puga ME, et al. (Cochrane Acute Respiratory Infections Group) (October 2023). "Vaccines for preventing herpes zoster in older adults". The Cochrane Database of Systematic Reviews. 2023 (10) CD008858. doi:10.1002/14651858.CD008858.pub5. PMC 10542961. PMID 37781954.
    Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, et al. (January 2018). "Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines" (PDF). MMWR. Morbidity and Mortality Weekly Report. 67 (3): 103–108. doi:10.15585/mmwr.mm6703a5. PMC 5812314. PMID 29370152. Archived (PDF) from the original on 29 August 2021. Retrieved 10 June 2023.
    Le P, Rothberg MB (February 2018). "Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults". JAMA Internal Medicine. 178 (2): 248–258. doi:10.1001/jamainternmed.2017.7431. PMC 5838796. PMID 29297049.
    Taquet M, Dercon Q, Todd JA, Harrison PJ (October 2024). "The recombinant shingles vaccine is associated with lower risk of dementia". Nature Medicine. 30 (10): 2777–2781. doi:10.1038/s41591-024-03201-5. PMC 11485228. PMID 39053634.
    Taquet M, Todd JA, Harrison PJ (June 2025). "Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections". npj Vaccines. 10 (1) 130. doi:10.1038/s41541-025-01172-3. PMC 12198376. PMID 40562756.
    dailymed.nlm.nih.gov
    "Zostavax – zoster vaccine live injection, powder, lyophilized, for suspension Sterile Diluent – sterile water injection". DailyMed. 26 September 2019. Archived from the original on 25 September 2020. Retrieved 6 September 2020.
    "Shingrix- zoster vaccine recombinant, adjuvanted kit". DailyMed. 4 October 2019. Archived from the original on 25 September 2020. Retrieved 6 September 2020.
    pharmaceuticalonline.com (Global: low place; English: low place)
    "FDA Licenses New Vaccine to Reduce Older Americans' Risk of Shingles" (Press release). U.S. Food and Drug Administration (FDA). 26 May 2006. Archived from the original on 12 November 2017. Retrieved 31 October 2009.
    publishing.service.gov.uk (Global: 1,837^th place; English: 948^th place)
    assets.publishing.service.gov.uk
    "Chapter 28a: Shingles (herpes zoster)". Green Book of immunisation (PDF). 23 August 2021. p. 8. Archived (PDF) from the original on 29 September 2021. Retrieved 11 November 2021. The need for booster doses of either Shingrix and Zostavax has not yet been determined.
    rxlist.com (Global: low place; English: low place)
    Cunha JP. "Zostavax Side Effects Center". RxList. Archived from the original on 5 January 2014. Retrieved 4 January 2014.
    semanticscholar.org (Global: 15^th place; English: 8^th place)
    api.semanticscholar.org
    Advisory Committee on Immunization Practices (November 2007). "Recommended adult immunization schedule: United States, October 2007-September 2008". Annals of Internal Medicine. 147 (10): 725–729. doi:10.7326/0003-4819-147-10-200711200-00187. PMID 17947396. S2CID 31630647.
    stanford.edu (Global: 194^th place; English: 182^nd place)
    med.stanford.edu
    "Study strengthens link between shingles vaccine and lower dementia risk". Stanford Medicine. 2 April 2025. Retrieved 13 May 2025.
    tga.gov.au (Global: 4,353^rd place; English: 2,806^th place)
    "Zostavax vaccine". Therapeutic Goods Administration (TGA) (Press release). 7 March 2017. Archived from the original on 12 July 2020. Retrieved 11 July 2020.
    "Zostavax vaccine". Therapeutic Goods Administration (TGA) (Press release). 6 July 2020. Archived from the original on 11 July 2020. Retrieved 11 July 2020.
    ubc.ca (Global: 1,820^th place; English: 998^th place)
    ti.ubc.ca
    "[114] Shingrix: A New Vaccine for Shingles". Therapeutics Initiative. 11 October 2018. Archived from the original on 14 October 2018. Retrieved 14 October 2018.
    "Therapeutics Initiative | [114] Shingrix: A New Vaccine for Shingles".
    "Therapeutics Initiative | [114] Shingrix: A New Vaccine for Shingles".
    walrus.com (Global: low place; English: low place)
    Staiger B (27 October 2019). "Are Dose One And Dose Two Of Shingrix The Same?". walrus. Archived from the original on 5 February 2024. Retrieved 5 February 2024.
    washingtonpost.com (Global: 35^th place; English: 24^th place)
    Cimons M (29 July 2018). "Don't panic if you're put on a waiting list for the new shingles vaccine". The Washington Post. Archived from the original on 5 August 2019. Retrieved 24 January 2020. The Centers for Disease Control and Prevention, which issues vaccine recommendations, says patients who wait longer than six months needn't worry, but they should get that second dose as soon as possible. Be sure not to skip it, because two doses convey the maximum immunity, more than 90%.
    web.archive.org (Global: 1^st place; English: 1^st place)
    "Zoster vaccine live (Zostavax) Use During Pregnancy". Drugs.com. 3 January 2020. Archived from the original on 16 May 2021. Retrieved 23 January 2020.
    "Zostavax vaccine – Summary of Product Characteristics (SmPC)". (emc). 28 January 2019. Archived from the original on 16 May 2021. Retrieved 6 September 2020.
    "Zostavax – zoster vaccine live injection, powder, lyophilized, for suspension Sterile Diluent – sterile water injection". DailyMed. 26 September 2019. Archived from the original on 25 September 2020. Retrieved 6 September 2020.
    "Shingrix- zoster vaccine recombinant, adjuvanted kit". DailyMed. 4 October 2019. Archived from the original on 25 September 2020. Retrieved 6 September 2020.
    "Zostavax EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 5 August 2020. Retrieved 31 July 2020.
    "Shingrix EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 4 August 2018. Retrieved 31 July 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
    Saguil A, Kane S, Mercado M, Lauters R (November 2017). "Herpes zoster and postherpetic neuralgia: prevention and management". American Family Physician. 96 (10): 656–663. PMID 29431387. Archived from the original on 25 April 2021. Retrieved 19 February 2021.
    "What everyone should know about Zostavax". U.S. Centers for Disease Control and Prevention (CDC). 18 June 2018. Archived from the original on 17 November 2018. Retrieved 16 November 2018.
    "Herpes Zoster Vaccination". U.S. Centers for Disease Control and Prevention (CDC). 31 July 2015. Archived from the original on 26 October 2021. Retrieved 26 October 2021.
    "Chapter 28a: Shingles (herpes zoster)". Green Book of immunisation (PDF). 23 August 2021. p. 8. Archived (PDF) from the original on 29 September 2021. Retrieved 11 November 2021. The need for booster doses of either Shingrix and Zostavax has not yet been determined.
    Han DH (25 October 2017). "ACIP: New Vaccine Recommendations for Shingles Prevention". MPR. Archived from the original on 11 May 2021. Retrieved 30 October 2017.
    Staiger B (27 October 2019). "Are Dose One And Dose Two Of Shingrix The Same?". walrus. Archived from the original on 5 February 2024. Retrieved 5 February 2024.
    "Shingles Vaccination: What Everyone Should Know". U.S. Centers for Disease Control and Prevention (CDC). 24 May 2022. Archived from the original on 20 April 2018. Retrieved 1 January 2023.
    "[114] Shingrix: A New Vaccine for Shingles". Therapeutics Initiative. 11 October 2018. Archived from the original on 14 October 2018. Retrieved 14 October 2018.
    "FDA Licenses New Vaccine to Reduce Older Americans' Risk of Shingles" (Press release). U.S. Food and Drug Administration (FDA). 26 May 2006. Archived from the original on 12 November 2017. Retrieved 31 October 2009.
    "Patient Information about Zostavax". U.S. Food and Drug Administration (FDA). May 2006. Archived from the original on 19 June 2009. Retrieved 31 October 2009.
    "Patient Information about Zostavax (Text) 12/2008". U.S. Food and Drug Administration (FDA). December 2008. Archived from the original on 27 August 2009. Retrieved 31 October 2009.
    "CDC's Advisory Committee Recommends "Shingles" Vaccination" (Press release). U.S. Centers for Disease Control and Prevention (CDC). 26 October 2006. Archived from the original on 5 November 2009. Retrieved 31 October 2009.
    "About Zostavax". Merck Sharp & Dohme Corp. May 2018. Archived from the original on 17 November 2018. Retrieved 16 November 2018.
    Harris S (18 January 2011). "Shingles Vaccine: Expert Q&A". WebMD. Archived from the original on 3 January 2014. Retrieved 4 January 2014.
    Cunha JP. "Zostavax Side Effects Center". RxList. Archived from the original on 5 January 2014. Retrieved 4 January 2014.
    "Zostavax vaccine". Therapeutic Goods Administration (TGA) (Press release). 7 March 2017. Archived from the original on 12 July 2020. Retrieved 11 July 2020.
    "Zostavax vaccine". Therapeutic Goods Administration (TGA) (Press release). 6 July 2020. Archived from the original on 11 July 2020. Retrieved 11 July 2020.
    "FDA Shingrix Briefing Document" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on 2 November 2017. Retrieved 28 October 2017.
    "Shingles Vaccine (Zoster Shingles Vaccine Live, Zostavax)". Medicinenet.com. Archived from the original on 12 November 2017. Retrieved 29 April 2018.
    Davidson MW (13 November 2015). "Human Fetal Lung Fibroblast Cells (MRC-5 Line)". Florida State University. Archived from the original on 27 April 2021. Retrieved 6 September 2020.
    Harpaz R, Ortega-Sanchez IR, Seward JF (June 2008). "Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)" (PDF). MMWR. Recommendations and Reports. 57 (RR-5): 1–30, quiz CE2–4. PMID 18528318. Archived (PDF) from the original on 8 June 2021. Retrieved 6 September 2020.
    Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, et al. (January 2018). "Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines" (PDF). MMWR. Morbidity and Mortality Weekly Report. 67 (3): 103–108. doi:10.15585/mmwr.mm6703a5. PMC 5812314. PMID 29370152. Archived (PDF) from the original on 29 August 2021. Retrieved 10 June 2023.
    "Zostavax EPAR" (PDF). European Medicines Agency (EMA). July 2006. Archived (PDF) from the original on 5 July 2019. Retrieved 27 March 2011.
    "Zostavax-H-C-674-II-03 Scientific Discussion" (PDF). 21 June 2007. Archived (PDF) from the original on 5 July 2019. Retrieved 27 March 2011.
    "Shingles Vaccination (16 July 2013, archived)". NHS UK. Archived from the original on 2 June 2014.
    "Who can have the shingles vaccine? (16 July 2013, archived)". NHS UK. Archived from the original on 10 April 2014.
    "Shingles vaccine overview". National Health Service (NHS). 31 August 2021. Archived from the original on 2 June 2014. Retrieved 26 November 2021.
    "FDA approves Zostavax vaccine to prevent shingles in individuals 50 to 59 years of age" (Press release). U.S. Food and Drug Administration (FDA). 24 March 2011. Archived from the original on 27 March 2011. Retrieved 27 March 2011.
    "BBL approval" (PDF). U.S. Food and Drug Administration (FDA). 20 October 2017. Archived from the original (PDF) on 1 November 2017. Retrieved 29 April 2018.
    "Shingles (Herpes Zoster) Vaccination". U.S. Centers for Disease Control and Prevention (CDC). Archived from the original on 7 December 2018.
    "Product Discontinuation Notice: Zostavax (Zoster Vaccine Live)" (PDF). Archived from the original (PDF) on 18 August 2020.
    Cimons M (29 July 2018). "Don't panic if you're put on a waiting list for the new shingles vaccine". The Washington Post. Archived from the original on 5 August 2019. Retrieved 24 January 2020. The Centers for Disease Control and Prevention, which issues vaccine recommendations, says patients who wait longer than six months needn't worry, but they should get that second dose as soon as possible. Be sure not to skip it, because two doses convey the maximum immunity, more than 90%.
    "Frequently Asked Questions About Shingrix". U.S. Centers for Disease Control and Prevention (CDC). 26 March 2018. Archived from the original on 1 May 2021. Retrieved 23 January 2020. You and patients should make every effort to ensure that two doses are administered within the recommended 2–6 month interval. If more than 6 months have elapsed since the first dose, administer the second dose as soon as possible. Do not restart the vaccine series...
    Report to the Congress: Medicare and the Health Care Delivery System. Medicare Payment Advisory Commission. June 2021. p. 254. Archived from the original on 24 May 2022. Retrieved 15 June 2022.
    webmd.com (Global: 2,056^th place; English: 1,884^th place)
    Harris S (18 January 2011). "Shingles Vaccine: Expert Q&A". WebMD. Archived from the original on 3 January 2014. Retrieved 4 January 2014.
    
    2020-2026
    CC BY-SA 4.0
    Terms of use
    
    BestRef.net (ver. 1.02)
    
    BestRef shows importance scores for websites and scholarly publications in Wikipedia references in different languages. Data extraction based on complex method using Wikimedia dumps. To find the best sources we used information about over 400 million references of Wikipedia articles. More details...
    
    Usefull links
    
    Wikipedia
    
    Go to top
    
    In Wikipedia verifiability we trust

Zoster vaccine (English Wikipedia)

aafp.org (Global: 2,559th place; English: 2,163rd place)

canada.ca (Global: 1,114th place; English: 605th place)

cdc.gov (Global: 251st place; English: 248th place)

cdc.gov

archive.cdc.gov

doi.org (Global: 2nd place; English: 2nd place)

drugs.com (Global: 529th place; English: 550th place)

empr.com (Global: low place; English: low place)

europa.eu (Global: 62nd place; English: 100th place)

ema.europa.eu

fda.gov (Global: 470th place; English: 329th place)

fsu.edu (Global: 2,949th place; English: 1,945th place)

micro.magnet.fsu.edu

gov.uk (Global: 401st place; English: 228th place)

medicinenet.com (Global: 6,975th place; English: 7,170th place)

medicines.org.uk (Global: 4,892nd place; English: 3,451st place)

medpac.gov (Global: low place; English: low place)

merckvaccines.com (Global: low place; English: low place)

nhs.uk (Global: 2,637th place; English: 2,254th place)

nih.gov (Global: 5th place; English: 5th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

pharmaceuticalonline.com (Global: low place; English: low place)

publishing.service.gov.uk (Global: 1,837th place; English: 948th place)

assets.publishing.service.gov.uk

rxlist.com (Global: low place; English: low place)

semanticscholar.org (Global: 15th place; English: 8th place)

api.semanticscholar.org

stanford.edu (Global: 194th place; English: 182nd place)

med.stanford.edu

tga.gov.au (Global: 4,353rd place; English: 2,806th place)

ubc.ca (Global: 1,820th place; English: 998th place)

ti.ubc.ca

walrus.com (Global: low place; English: low place)

washingtonpost.com (Global: 35th place; English: 24th place)

web.archive.org (Global: 1st place; English: 1st place)

webmd.com (Global: 2,056th place; English: 1,884th place)

aafp.org (Global: 2,559^th place; English: 2,163^rd place)

canada.ca (Global: 1,114^th place; English: 605^th place)

cdc.gov (Global: 251^st place; English: 248^th place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugs.com (Global: 529^th place; English: 550^th place)

europa.eu (Global: 62^nd place; English: 100^th place)

fda.gov (Global: 470^th place; English: 329^th place)

fsu.edu (Global: 2,949^th place; English: 1,945^th place)

gov.uk (Global: 401^st place; English: 228^th place)

medicinenet.com (Global: 6,975^th place; English: 7,170^th place)

medicines.org.uk (Global: 4,892^nd place; English: 3,451^st place)

nhs.uk (Global: 2,637^th place; English: 2,254^th place)

nih.gov (Global: 5^th place; English: 5^th place)

publishing.service.gov.uk (Global: 1,837^th place; English: 948^th place)

semanticscholar.org (Global: 15^th place; English: 8^th place)

stanford.edu (Global: 194^th place; English: 182^nd place)

tga.gov.au (Global: 4,353^rd place; English: 2,806^th place)

ubc.ca (Global: 1,820^th place; English: 998^th place)

washingtonpost.com (Global: 35^th place; English: 24^th place)

web.archive.org (Global: 1^st place; English: 1^st place)

webmd.com (Global: 2,056^th place; English: 1,884^th place)